Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

ABSTRACT:

Background

Administration of intensive induction chemotherapy followed by consolidation with postremission high- or intermediate-dose cytarabine (H/IDAC) remains a standard therapeutic approach in fit patients with nonadverse risk acute myeloid leukemia (AML). Historically, H/IDAC has been administered in the inpatient (IP) rather than outpatient (OP) setting given infection risk, transfusion and supportive care needs, and logistical challenges of OP treatment. However, the financial toxicity associated with IP chemotherapy hospitalization as well as risk of nosocomial infections and improvements in antimicrobial prophylaxis have highlighted the potential role for OP H/IDAC administration.

Methods

Accordingly, an OP H/IDAC treatment program was developed at Memorial Sloan Ke

SUBMITTER: Burton H 

PROVIDER: S-EPMC12330780 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature